... This study aimed to clarify the mechanism of resistance to alectinib in LMC and seek a novel therapeutic strategy... Our findings may provide rationale for clinical trials to investigate the effects of novel therapies dual-targeting ALK and EGFR in ALK-rearranged NSCLC with alectinib-resistant LMC. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.12.076
Authors: S. Yano, S. Arai, K. Fukuda, S. Takeuchi
Summary: Over the past decade, tremendous progress has been made in understanding the molecular and biologic drivers of lung cancer. Testing for various biomarkers in lung cancer is improving our ability to understand the behavior of different cancers, so we can identify the optimal treatment strategy for each clinical subset of patients. This progress has helped us to deliver individualized precision therapy options for our patients with lung cancer. Ongoing clinical trials will help to improve our... READ ARTICLE
Surgical Oncology Clinics of North America DOI:Precision Medicine in Lung Cancer Treatment
Authors: Dhaval R. Shah, Gregory A. Masters
